UNSPSC 51342709: Interferon beta-1a

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XRO4566Q4R. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12440MIG. As of Q4 2014, INTERFERON BETA-1A remains the US FDA Preferred Term for this commodity. Interferon beta-1a bears US NLM identifiers UMLS ID C0982234 and NCI Concept Code C1823. SMILES: NONE.

UNSPSC 51342709 Interferon beta-1a is a Commodity code that in practice covers pharmaceuticals and medical supplies procured by state and local health agencies, but the recent opportunities tagged under this code show little alignment with the nominal product category. The recorded state and local solicitations under this code address broader pharmaceutical procurement, emergency medical supplies, and pharmacy benefit program management rather than the specific interferon beta-1a immunotherapy product the code nominally identifies. State and local health departments, fire departments, and cooperative purchasing alliances are the primary issuing bodies, reflecting the distributed nature of pharmaceutical procurement across government health systems, emergency services, and multistate cooperative vehicles. The work being solicited includes emergency response medical consumables (cardiac monitoring electrodes, endotracheal tubes, respiratory equipment, oxygen delivery systems), generic multistate pharmaceutical contracts with authorized wholesalers, and exploratory pharmacy benefit initiatives to improve prescription fulfillment efficiency through direct-to-manufacturer relationships outside traditional pharmacy benefit manager channels.

Recent activity spans Texas, Minnesota, Florida, and Oregon. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with contract effectiveness July 1, 2026 and vendor submissions through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. The City of Tampa Purchasing Department issued an IFB (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division at an estimated contract value of $700,000.00, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. Seminole County, Florida posted an IFB (due July 26, 2023) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, supported through potential FEMA funding. The Texas Health and Human Services Commission issued an RFI (posted April 3, 2026, due April 3, 2026) to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed as foundational market intelligence before formal RFP issuance.